

Exocrine Pancreatic Insufficiency Market to Register Incremental Growth from (2024-2034), Asserts DelveInsight

DelveInsight's Exocrine Pancreatic Insufficiency Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, June 13, 2024 /EINPresswire.com/ --

DelveInsight's "Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Exocrine

Pancreatic Insufficiency, historical and

forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Exocrine Pancreatic Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Exocrine Pancreatic Insufficiency Market Forecast](#)

Some of the key facts of the Exocrine Pancreatic Insufficiency Market Report:

The Exocrine Pancreatic Insufficiency market size was valued approximately USD 2,500 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

In December 2023, Codexis, Inc. (NASDAQ: CDXS), a prominent enzyme engineering firm, announced a purchase agreement with Nestlé Health Science, a globally recognized leader in nutritional science, for CDX-7108, an investigational treatment for exocrine pancreatic insufficiency (EPI). According to the agreement, Codexis will receive up to \$45 million in potential milestone payments, including an upfront payment of \$5 million, as well as single-digit royalties based on net sales. Additionally, Codexis could receive up to \$5 million more if Nestlé Health Science opts to purchase two additional early-stage enzymes being developed for EPI.



Exocrine Pancreatic Insufficiency Market Insights

Within the 7MM, the United States recorded the highest prevalence of EPI, with a total of 176,112 cases in 2021, and projections indicate a further increase during the forecast period (2022–2032).

According to Delveinsight's analysis in Germany, there were a combined total of 10,088, 24,665, 5,792, and 4,704 cases of EPI resulting from Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis, and Unresectable Pancreatic Cancer, respectively, in the year 2021.

Key Exocrine Pancreatic Insufficiency Companies: Digestive Care, Solvay Pharmaceuticals, First Wave Biopharma, Anagram Therapeutics, First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories, First Wave BioPharma, Inc., Anthera Pharmaceuticals, and others

Key Exocrine Pancreatic Insufficiency Therapies: PERTZYE, CREON, FW-EPI (adrulipase), ANG003, FWEPI/MS1819, Pancreatin, VIOKASE 16, Pancrelipase Delayed Release, SA-001, EUR-1008, adrulipase, Liprotamase, and others

The Exocrine Pancreatic Insufficiency epidemiology based on gender analyzed that No gender difference was observed in the case of EPI

The Exocrine Pancreatic Insufficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Exocrine Pancreatic Insufficiency pipeline products will significantly revolutionize the Exocrine Pancreatic Insufficiency market dynamics.

Exocrine Pancreatic Insufficiency Overview

Exocrine Pancreatic Insufficiency (EPI) is a condition where the pancreas is unable to produce and release enough digestive enzymes into the small intestine to properly break down and absorb nutrients from food. These digestive enzymes, including lipase, protease, and amylase, play a crucial role in the digestion of fats, proteins, and carbohydrates.

Get a Free sample for the Exocrine Pancreatic Insufficiency Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Exocrine Pancreatic Insufficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Exocrine Pancreatic Insufficiency Epidemiology Segmentation:

The Exocrine Pancreatic Insufficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Exocrine Pancreatic Insufficiency

Prevalent Cases of Exocrine Pancreatic Insufficiency by severity

Gender-specific Prevalence of Exocrine Pancreatic Insufficiency

Diagnosed Cases of Episodic and Chronic Exocrine Pancreatic Insufficiency

Download the report to understand which factors are driving Exocrine Pancreatic Insufficiency epidemiology trends @ [Exocrine Pancreatic Insufficiency Epidemiology Forecast](#)

Exocrine Pancreatic Insufficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency market or expected to get launched during the study period. The analysis covers Exocrine Pancreatic Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Exocrine Pancreatic Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Exocrine Pancreatic Insufficiency Therapies and Key Companies

PERTZYE: Digestive Care

CREON: Solvay Pharmaceuticals

FW-EPI (adrulipase): First Wave Biopharma

ANG003: Anagram Therapeutics

FWEPI/MS1819: First Wave BioPharma

Pancreatin: Abbott Products

VIOKASE 16: AAIPharma

Pancrelipase Delayed Release: Solvay Pharmaceuticals

SA-001: Abbott

EUR-1008: Forest Laboratories

adrulipase: First Wave BioPharma, Inc.

Liprotamase: Anthera Pharmaceuticals

Exocrine Pancreatic Insufficiency Market Drivers

Delivery system strategies

Advanced therapeutics for the treatment of exocrine pancreatic insufficiency

Increasing global occurrence of exocrine pancreatic insufficiency

Research and developmental strategies

Exocrine Pancreatic Insufficiency Market Barriers

Lack of technological reach and awareness

Lack of confidence in diagnosis and management

Treatment failure to stimulate and follow society's goals and requirements

Scope of the Exocrine Pancreatic Insufficiency Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Exocrine Pancreatic Insufficiency Companies: Digestive Care, Solvay Pharmaceuticals, First Wave Biopharma, Anagram Therapeutics, First Wave BioPharma, Abbott Products, AAI Pharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories, First Wave BioPharma, Inc., Anthera Pharmaceuticals, and others

Key Exocrine Pancreatic Insufficiency Therapies: PERTZYE, CREON, FW-EPI (adrulipase), ANG003, FWEPI/MS1819, Pancreatin, VIOKASE 16, Pancrelipase Delayed Release, SA-001, EUR-1008, adrulipase, Liprotamase, and others

Exocrine Pancreatic Insufficiency Therapeutic Assessment: Exocrine Pancreatic Insufficiency current marketed and Exocrine Pancreatic Insufficiency emerging therapies

Exocrine Pancreatic Insufficiency Market Dynamics: Exocrine Pancreatic Insufficiency market drivers and Exocrine Pancreatic Insufficiency market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Exocrine Pancreatic Insufficiency Unmet Needs, KOL's views, Analyst's views, Exocrine Pancreatic Insufficiency Market Access and Reimbursement

To know more about Exocrine Pancreatic Insufficiency companies working in the treatment market, visit @ [Exocrine Pancreatic Insufficiency Clinical Trials and Treatment](#)

Table of Contents

1. Exocrine Pancreatic Insufficiency Market Report Introduction
2. Executive Summary for Exocrine Pancreatic Insufficiency
3. SWOT analysis of Exocrine Pancreatic Insufficiency
4. Exocrine Pancreatic Insufficiency Patient Share (%) Overview at a Glance
5. Exocrine Pancreatic Insufficiency Market Overview at a Glance
6. Exocrine Pancreatic Insufficiency Disease Background and Overview
7. Exocrine Pancreatic Insufficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Exocrine Pancreatic Insufficiency
9. Exocrine Pancreatic Insufficiency Current Treatment and Medical Practices

10. Exocrine Pancreatic Insufficiency Unmet Needs
11. Exocrine Pancreatic Insufficiency Emerging Therapies
12. Exocrine Pancreatic Insufficiency Market Outlook
13. Country-Wise Exocrine Pancreatic Insufficiency Market Analysis (2020–2034)
14. Exocrine Pancreatic Insufficiency Market Access and Reimbursement of Therapies
15. Exocrine Pancreatic Insufficiency Market Drivers
16. Exocrine Pancreatic Insufficiency Market Barriers
17. Exocrine Pancreatic Insufficiency Appendix
18. Exocrine Pancreatic Insufficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/719793835>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.